Skip to main content
Pharmanutra logo

Pharmanutra — Investor Relations & Filings

Ticker · PHN ISIN · IT0005274094 LEI · 815600F8217BC7733697 XMIL Manufacturing
Open in API
Filings indexed 601 across all filing types
Latest filing 2024-05-22 AGM Information
Country IT Italy
Listing XMIL PHN

About Pharmanutra

http://www.pharmanutra.it

PharmaNutra is a company operating in the pharmaceutical and nutraceutical sectors, focused on the development and distribution of nutritional supplements and medical devices. Grounded in scientific research, the company creates innovative solutions for health and wellness. Its core activities center on addressing nutritional deficiencies, particularly iron, through proprietary functional ingredients and technologies. The product portfolio also extends to supporting muscle and joint health, sports nutrition, and applications across various therapeutic areas, including gynecology, orthopedics, hematology, and gastroenterology. The company emphasizes the development of effective and safe products supported by clinical evidence.

Recent filings

Filing Released Lang Actions
Verbale Assemblea 16 aprile 2024
AGM Information Classification · 1% confidence The document is explicitly titled "VERBALE DI ASSEMBLEA" (Minutes of the Meeting) and details the proceedings, attendance verification, quorum establishment, and the agenda items discussed for the shareholders' meeting of 'Pharmanutra S.p.A.' held on April 16, 2024. The agenda includes approval of the 2023 financial statements (Bilancio di esercizio), remuneration policy, and share buyback authorization. This content is characteristic of the official minutes recorded by a notary following an Annual General Meeting (AGM). Although it covers AGM topics, the document itself is the formal record/minutes, which aligns best with the 'AGM Information' category (AGM-R), as it documents the meeting itself, rather than just a presentation (IP) or the voting results (DVA).
2024-05-22 Italian
Interim management report as at 31 March 2024
Interim / Quarterly Report Classification · 1% confidence The document is titled 'INTERIM MANAGEMENT STATEMENT AS AT 31 MARCH 2024' and contains detailed consolidated financial statements, including the balance sheet, income statement, and cash flow statement for the first quarter of 2024. It provides a comprehensive analysis of the group's performance, business lines, and outlook. As it contains substantive financial data for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. Q1 2024
2024-05-15 English
Resoconto intermedio di gestione al 31 marzo 2024
Interim / Quarterly Report Classification · 1% confidence The document is titled 'RESOCONTO INTERMEDIO DI GESTIONE AL 31 MARZO 2024' (Interim Management Report as of March 31, 2024). It contains comprehensive financial data, including consolidated balance sheets, income statements, cash flow statements, and management commentary for the first quarter of 2024. It is not an announcement of a report, but the report itself, and it provides substantive financial analysis, fitting the definition of an Interim/Quarterly Report. Q1 2024
2024-05-15 Italian
Resoconto intermedio di gestione_Interim managment report
Report Publication Announcement Classification · 1% confidence The document explicitly states its subject ('Oggetto') as 'Resoconto intermedio di gestione_Interim managment report' and the title confirms 'FILING OF THE INTERIM MANAGEMENT REPORT AS OF MARCH 31, 2024'. An 'Interim Management Report' corresponds to a comprehensive financial report for a period shorter than a year, which aligns with the definition of an Interim / Quarterly Report (Code: IR). Although it mentions the report is available ('Vedi allegato'), the document itself is the announcement/filing of this specific report type, not just a generic announcement of publication (RPA). Since the content describes the filing of a specific periodic report, IR is the most accurate classification over RPA or RNS. The length (7865 chars) is substantial enough to be the filing itself rather than a brief notice.
2024-05-15 Italian
Pharmanutra - Results at 31 March 2024 approved
Earnings Release Classification · 1% confidence The document is a press release from PharmaNutra S.p.A. announcing the approval of its Interim Management Report for the period ending 31 March 2024. While it contains summary financial tables (EBITDA, Net Result, Balance Sheet), it is structured as a corporate announcement (press release) rather than the full, formal interim report itself. According to the 'Menu vs Meal' rule, this is an announcement of results, which falls under the Earnings Release (ER) category as it provides key highlights of the quarterly performance. Q1 2024
2024-05-13 English
Pharmanutra_Approvati i risultati al 31 marzo 2024
Interim / Quarterly Report Classification · 1% confidence The document is a comprehensive financial report for the first quarter (period ending March 31, 2024) of PharmaNutra S.p.A. It contains detailed financial statements, including income statements, balance sheet data, and analysis of results, revenue by product line, and management's outlook. Although it is titled as a 'Resoconto Intermedio di Gestione' (Interim Management Report), it provides substantive financial data and analysis, fitting the definition of an Interim/Quarterly Report (IR). It is not merely an announcement of a report, as it contains the actual financial tables and performance commentary. Q1 2024
2024-05-13 Italian

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.